Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma

@article{Dimopoulos2008ThalidomidePD,
  title={Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma},
  author={Meletios Athanasios Dimopoulos and Efstathios Kastritis},
  journal={Nature Clinical Practice Oncology},
  year={2008},
  volume={5},
  pages={690-691}
}
Thalidomide with dexamethasone (thal-dex) is an active therapy for patients with relapsed or refractory multiple myeloma (MM). In this Practice Point, we discuss the findings of a trial by Rajkumar et al. that aimed to compare the response rate, time to progression and progression-free survival among previously untreated patients with MM who received either thal-dex or placebo plus dexamethasone. The thal-dex regimen was associated with a significantly higher response rate at the expense of… CONTINUE READING